profit from every $100 of sales.
$0$100
Neurocrine Biosciences
$167.40-1.18% today
+16.1% in 1 year
1-year low $123.101-year high $185.50
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2020 to 2025.
0%20% a year
You pay $35.40 for every $1 of profit it makes in a year.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Neurocrine Biosciences sold, what it kept, and what it did with the cash.
Sales went from $1.49 billion in 2022 to $2.86 billion in 2025, with $479 million of profit last year.
SalesProfit
Neurocrine Biosciences handed back 22% of the cash it generated last year.
Buybacks $168M
Free cash flow 2025$749M
Bought back its own shares$168M
Paid as dividends–
Cash vs. debt$713M vs. $415M
Neurocrine Biosciences vs. similar companies
Neurocrine Biosciences grows the fastest of these 5 and is priced in the middle for its profits.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Neurocrine Biosciences | 35.4× · Expensive | ||
 Merck KGaA | 24.9× · Fair price | ||
 Takeda Pharmaceutical | 102.5× · Very expensive | ||
 Galderma Group | 86.9× · Very expensive | ||
 Teva Pharmaceutical Industries | 36.8× · Expensive |
AI analysis
An AI analyst reads Neurocrine Biosciences's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| 1,046 | 1,134 | 1,489 | 1,887 | 2,355 | 2,861 | |
| 1,036 | 1,119 | 1,466 | 1,847 | 2,321 | 2,808 | |
| 163 | 103 | 249 | 395 | 583 | 637 | |
| 148 | 138 | 265 | 416 | 640 | 667 | |
| 407 | 90 | 155 | 250 | 341 | 479 | |
| 4.16 | 0.92 | 1.56 | 2.47 | 3.29 | 4.67 | |
| 99.0% | 98.7% | 98.4% | 97.9% | 98.6% | 98.2% | |
| 15.6% | 9.0% | 16.7% | 20.9% | 24.8% | 22.3% | |
| 38.9% | 7.9% | 10.4% | 13.2% | 14.5% | 16.7% |
Balance sheet
| In millions of USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Total assets | 1,735 | 2,073 | 2,369 | 3,251 | 3,719 | 4,632 |
| Cash | 187 | 341 | 263 | 251 | 233 | 713 |
| Total debt | – | – | 263 | 428 | 455 | 415 |
| Total liabilities | 609 | 699 | 661 | 1,019 | 1,129 | 1,378 |
| 1,126 | 1,374 | 1,708 | 2,232 | 2,590 | 3,253 | |
| 98 | 98 | 99 | 101 | 104 | 103 | |
| 9.8% | 7.3% | 10.0% | 11.7% | 15.9% | 13.7% | |
| 36.2% | 6.5% | 9.0% | 11.2% | 13.2% | 14.7% |
Cash flow
| In millions of USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| 229 | 257 | 339 | 390 | 595 | 783 | |
| 11 | 23 | 17 | 28 | 38 | 34 | |
| 218 | 233 | 323 | 362 | 557 | 749 | |
| Dividends paid | – | – | – | – | – | – |
| – | – | 0 | 0 | 300 | 168 | |
| 100 | 134 | 173 | 194 | 196 | 218 |
Valuation
- 35.4×
- 27.4×
- 15.13
- 4.4×
- 5.9×
- 22.6×
- 25.0×
- 4.4%
- 2.8%
- 0.0%
Profitability
- 98.2%
- 22.3%
- 16.7%
- 28.4%
- 13.7%
- 9.3%
- 21.6%
- 13.6%
- 19.2%
- 33.8%
Growth
- +22.3%
- +2.3%
- +34.4%
- –
- +1.3%
Financial health
- 0.2×
- 0.12
- 8.3%
- –
- 2.93
- 2.85
- 0.63
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Top 17%of 946
Top 19%of 872
Bottom 38%of 563
Top 26%of 868
Top 24%of 986
What analysts expect
- Average price target
- $178.09
- Range
- $140.00 – $220.00
- 9 analysts
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 5, 2026 | 1.94 | 1.28 | +51.6% |
| Feb 11, 2026 | 1.88 | 1.80 | +4.4% |
| Oct 28, 2025 | 2.04 | 1.58 | +29.1% |
| Jul 30, 2025 | 1.06 | 0.98 | +8.2% |
| May 5, 2025 | 0.08 | 0.54 | −85.0% |
| Feb 6, 2025 | 1.00 | 1.62 | −38.3% |
| Oct 30, 2024 | 1.24 | 1.51 | −17.9% |
| Aug 1, 2024 | 0.63 | 1.05 | −40.0% |
News
Where Will Neurocrine Biosciences Be in 5 Years?Yahoo Finance · Oct 25, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
2/7Passes 2 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
60Pass
Benjamin Graham
51No pass
Philip Fisher
61Pass
Peter Lynch
36No pass
Joel Greenblatt
20No pass
Charlie Munger
58No pass
Terry Smith
57No pass
Questions about Neurocrine Biosciences
Is Neurocrine Biosciences a good stock to buy?
A solid business, but the price is high. 2 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Neurocrine Biosciences AI analysis
What does Neurocrine Biosciences do?
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. It is in Drug Manufacturers - Specialty & Generic, based in San Diego, CA, United States, with 2,000 employees.
Does Neurocrine Biosciences pay a dividend?
No. Neurocrine Biosciences does not pay a dividend at the moment; in 2025 it returned $168 million to shareholders by buying back its own shares.
Is Neurocrine Biosciences stock halal?
Yes. Neurocrine Biosciences passes our halal screen: its business is permitted and its debt is 2% of its market value, under the 30% limit. How we check
How has Neurocrine Biosciences stock done over the past year?
Up 16.1% over the past twelve months, to $167.40. It traded between $123.10 and $185.50 and is 9.8% below its high.
Who are Neurocrine Biosciences's competitors?
The largest listed companies in the same industry are Merck KGaA, Takeda Pharmaceutical, Galderma Group and Teva Pharmaceutical Industries. The peers table on this page compares their profit, growth and price with Neurocrine Biosciences's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.